Ligand id: 6822

Name: hydroxyurea

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 3
Rotatable bonds 1
Topological polar surface area 75.35
Molecular weight 76.03
XLogP -1.61
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used to treat melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. In the US, the FDA has approved hydroxyurea to treat Sickle-cell anemia in adults, as shown by the presence of hemoglobin S. The FDA has subsequently granted orphan designation for the treatment of Sickle-cell disease in pediatric and young adult patient groups (2005-2015). The EMA has also granted hydroxyurea orphan designation the treatment of sickle cell syndrome (2003)
Mechanism Of Action and Pharmacodynamic Effects
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase